INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (Nasdaq: INVO) on June 15, 2021, reporting events occurring on June 14, 2021. The filing addresses significant changes in the company's executive management team, specifically within the finance function.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure of Principal Officer: Debra Hoopes resigned as Acting Chief Financial Officer effective June 14, 2021. The resignation was not due to any disagreement with the company regarding operations, policies, or practices.
- Appointment of Principal Officer: Andrea Goren was appointed Chief Financial Officer effective June 14, 2021.
Management Commentary and Compensation Details
Andrea Goren brings over 25 years of experience in private equity, investment banking, and corporate finance. His compensation package includes:
- Base Salary: $215,000 annually.
- Performance Bonus: Eligible for up to 50% of base salary based on milestones determined by the board.
- Equity Grant: 5,000 shares of common stock.
- Stock Options: A three-year option to purchase 72,500 shares at an exercise price of $5.205 per share.
Vesting Schedule: The equity awards will not commence vesting or become exercisable until January 1, 2022, contingent upon the availability of sufficient shares under the 2019 Stock Incentive Plan. Upon commencement, 12,083 shares will vest immediately, with the remainder vesting monthly over a three-year period.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as Exhibit 10.1 for complete terms and conditions.
- Confirm the status of the 2019 Stock Incentive Plan to ensure shares will be available for vesting as of January 1, 2022.
- Review the press release filed as Exhibit 99.1 for additional public commentary on the leadership transition.
- Monitor future filings for the company's next quarterly or annual report to assess the impact of the new CFO on financial strategy.